Quantcast

Industry news that matters to you.  Learn more

Doctors Create ‘MAGIC Algorithm’ to Predict Bone Marrow Transplant Patients’ Risk of Dying

Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, according to a study published in JCI (The Journal of Clinical Investigation) Insight.

Emerging Biomarkers Disrupt Cardiac Diagnostics

Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for the diagnosis of cardiac diseases, end users will soon see additional alternative biomarkers entering the market. By 2024, emerging biomarkers, such as ST2 Galectin-3, are becoming more sensitive in diagnosing cardiovascular disease will penetrate the lab-based and point-of-care (POC) end user segments.

Heart Failure Study Performed by Cleveland Clinic Shows Serial Testing with Cardiac Biomarker ST2 Predicts Outcomes of Hospitalized Patients

Critical Diagnostics recently reported that an abstract, “Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure,” presented at the American College of Cardiology Scientific Sessions in San Diego in March demonstrated in hospitalized heart failure patients that elevated levels of the cardiac biomarker ST2 were associated with an increased risk of adverse events. Authors include W.H. Wilson Tang of Cleveland Clinic, and Michael Felker and Christopher O’Connor of Duke University Medical Center and Duke Clinical Research Institute.

Opinions of 18 World-renowned Experts Contained in Consensus Paper on Role of Cardiac Biomarker ST2 in Heart Failure Care

Critical Diagnostics recently reported that The American Journal of Cardiology released an online version of a comprehensive consensus paper discussing the evidence base behind the evolving role of the cardiac biomarker ST2 and its appropriate uses in the management of patients with heart failure and related cardiac diseases.

International Panel of Experts Examine the Evolving Role of ST2 in Treating Cardiovascular Disease Patients

Critical Diagnostics recently announced that a group of eminent leaders in the field of cardiology from around the world gathered to discuss the evidence base behind the evolving role of the cardiac biomarker ST2 in the management of patients with heart failure and related diseases. The panels’ findings are expected to be published later this year.